Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

STADA and Xbrane ranibizumab development deal with Bausch + Lomb discontinued

Jul 25, 2023

STADA and Xbrane announced that their commercialization agreement with Bausch + Lonb has been terminated, and that they are considering options for their co-developed ranibizumab biosimilar  to Genentech’s Lucentis® (Ximluci®) in North America.

Xbrane entered into a co-development agreement with STADA Arzneimittel AG in 2018, and subsequently, in May 2020, the two companies signed an exclusive licensing agreement with Bausch + Lomb to bring the biosimilar candidate to market in the United States and Canada.

After receiving EU approval in November 2022, STADA and Xbrane intend to commercialise the product in the US.  On 22 June 2023, Xbrane announced the FDA has accepted a supplemental Biologics License Application (sBLA) for  (Ximluci®).